RE: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes by Williams, Thomas & Stewart, Emma
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RE: Semaglutide and Cardiovascular Outcomes in Patients with
Type 2 Diabetes
Citation for published version:
Williams, T & Stewart, E 2017, 'RE: Semaglutide and Cardiovascular Outcomes in Patients with Type 2
Diabetes' The New England Journal of Medicine, vol. 376, no. 9, pp. 890-892. DOI:
10.1056/NEJMc1615712
Digital Object Identifier (DOI):
10.1056/NEJMc1615712
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
The New England Journal of Medicine
Publisher Rights Statement:
Deposit permitted by the publisher.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 376;9 nejm.org March 2, 2017890
Muhammad H. Majeed, M.D.
Natchaug Hospital 
Mansfield Center, CT 
hassan . majeed@ icloud . com
Fahad Saeed, M.D.
University of Rochester Medical Center 
Rochester, NY
Disclosure forms provided by the authors are available with 
the full text of this letter at NEJM.org.
This letter was published on February 1, 2017, at NEJM.org.
1. Educational Commission for Foreign Medical Graduates; 
ECFMG 2015 Annual Report. April 2016 (http://www .ecfmg .org/ 
resources/ ECFMG-2015-annual-report .pdf).
2. Mullan F, Salsberg E, Weider K. Why a GME squeeze is un-
likely. N Engl J Med 2015; 373: 2397-9.
DOI: 10.1056/NEJMc1616421
Semaglutide and Cardiovascular Outcomes in Patients  
with Type 2 Diabetes
To the Editor: In reporting the results of the 
Trial to Evaluate Cardiovascular and Other Long-
term Outcomes with Semaglutide in Subjects 
with Type 2 Diabetes (SUSTAIN-6), Marso et al. 
(Nov. 10 issue)1 describe a lower rate of cardio-
vascular events among patients with type 2 dia-
betes mellitus who received the glucagon-like 
peptide 1 (GLP-1) analogue semaglutide than 
among patients who received placebo. Their re-
sults are consistent with those in the Liraglutide 
Effect and Action in Diabetes: Evaluation of Car-
diovascular Outcome Results (LEADER) trial,2 
which assessed the effects of another GLP-1 ana-
logue, liraglutide.
In SUSTAIN-6, the use of insulin at trial entry 
was similar between the two groups. However, 
during the LEADER trial, the use of insulin was 
approximately two times higher in the placebo 
group than in the liraglutide group, and during 
SUSTAIN-6, the use of insulin was approximately 
three times higher in the placebo group than in 
the semaglutide group. The significantly greater 
use of insulin in the placebo groups in these two 
trials may, at least in part, explain the increase 
in the risk of death from any cause as well as the 
increase in the risks of heart failure, cardiovas-
cular events, renal failure, and hypoglycemia in 
these two groups. Hazard ratios for these events 
associated with increased use of insulin range 
from 1.23 to 4.57, as shown in two cohort stud-
ies in primary care.3,4 Thus, we wonder whether 
the greater use of insulin in the placebo groups 
than in the liraglutide and semaglutide groups 
during these trials may have amplified the benefi-
cial effects of liraglutide and semaglutide.
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To the Editor: Marso et al. report diabetic reti-
nopathy complications in patients with type 2 dia-
betes who received semaglutide; this raises the 
possibility that GLP-1–receptor agonists could 
cause progression of diabetic retinopathy. The 
authors cite seminal studies involving patients 
with type 1 diabetes and suggest that progres-
sion of diabetic retinopathy is due to the glucose-
lowering effect of treatment.1 Studies involving 
patients with type 2 diabetes,2,3 albeit smaller 
and retrospective, also have shown similar find-
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ings: diabetic retinopathy progressed after the 
initiation of either intensive diabetes case man-
agement (the use of medications and other inter-
ventions to improve glucose control)2 or insulin 
therapy.3 Furthermore, such studies suggest that 
decrements of more than 2% in glycated hemo-
globin levels are associated with progression of 
diabetic retinopathy.2,4
In SUSTAIN-6, among patients who had an 
initial decrease in the glycated hemoglobin level, 
it is very likely that many patients had a greater 
than 2% decrease in the glycated hemoglobin 
level. Did progression of diabetic retinopathy oc-
cur predominantly in that group? Addressing the 
relationship between the decrease in the glycated 
hemoglobin level and progression of retinopathy 
might provide further guidance to clinicians treat-
ing patients with diabetic retinopathy and glycat-
ed hemoglobin levels that are high enough to 
permit a greater than 2% decrease with effective 
therapies. It also might help to address a potential 
causal relationship between GLP-1–receptor ago-
nists and the progression of diabetic retinopathy.
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To the Editor: Marso et al. state that with the 
exception of the complications of retinopathy, 
semaglutide had a safety profile that was similar 
to that of other GLP-1 agonists, such as liraglu-
tide, in patients with type 2 diabetes. However, 
the authors do not report the causes of death for 
the 18 patients in the intervention group (as com-
pared with 14 in the placebo group) who died 
from noncardiovascular causes.
They cite the LEADER trial1 to establish the 
safety of liraglutide. The LEADER trial showed 
that liraglutide was associated with a significant 
reduction not only in the primary composite out-
come of death from cardiovascular causes, non-
fatal myocardial infarction, or nonfatal stroke, but 
also in death from any cause (hazard ratio, 0.85; 
95% confidence interval, 0.74 to 0.97; P = 0.02).
Given that SUSTAIN-6 was designed to estab-
lish the safety of a new agent, will the authors 
comment on the noncardiovascular causes of death 
in the participants? Also, why was the rate of 
death from any cause lower among patients who 
received liraglutide than among those who re-
ceived placebo in the LEADER trial but not lower 
among those who received semaglutide than 
among those who received placebo in SUSTAIN-6?
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The authors reply: Cosmi et al. cite observa-
tional studies that associate insulin use with in-
creased cardiovascular risk, and they suggest that 
the greater new use of insulin in the placebo 
group than in the semaglutide group may have 
contributed to the difference in cardiovascular 
risk observed with semaglutide. However, the 
ORIGIN (Outcome Reduction with an Initial 
Glargine Intervention) trial,1 a large-scale, ran-
domized, controlled trial evaluating a potential 
cardiovascular effect of insulin, showed that in-
sulin glargine, as compared with placebo, was 
not associated with an increased cardiovascular 
risk. We therefore do not think that the use of 
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insulin contributed to the effect seen in our trial. 
However, exploratory analyses have been designed 
to address this question and other hypotheses 
regarding cardiovascular benefit.
Ipp et al. inquire about the increased rates of 
diabetic retinopathy complications among patients 
who received semaglutide as compared with 
those who received placebo, and they mention 
additional studies that indicate an effect of rapid 
glucose lowering on progression of retinopathy 
in patients with type 2 diabetes. They suggest 
the evaluation of patients with large initial de-
creases in blood glucose levels (reflected by de-
creases in glycated hemoglobin levels) in our trial. 
We agree that a rapid decrease in blood glucose 
levels may be a possible contributor to observed 
differences in diabetic retinopathy complications 
in the two groups in our trial.
Williams and Stewart inquire about noncar-
diovascular causes of death. Rates of noncardio-
vascular death were low and causes of noncar-
diovascular death were balanced between the trial 
groups (Table 1). The LEADER trial showed an 
effect of liraglutide on the rate of death from 
cardiovascular causes, but not on the rate of death 
from noncardiovascular causes. In our trial, we 
saw no effect on the rate of death from cardio-
vascular causes, possibly because semaglutide 
had no true effect, or because a true effect was 
not identified, given the limited number of events 
and short duration of follow-up. The duration of 
follow-up was approximately two times as long 
in the LEADER trial as in SUSTAIN-6, and the 
sample size was approximately three times as 
large.
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Variable
Semaglutide 
 (N = 1648)
Placebo 
 (N = 1649)
number of patients (percent)
Deaths from noncardiovascular causes 18 (1.1) 14 (0.8)
Cause of death
Cancer 8 (0.5) 6 (0.4)
Infection, including sepsis 5 (0.3) 4 (0.2)
Gastrointestinal disorder 2 (0.1) 0
Pulmonary disorder 0 2 (0.1)
Hemorrhage not attributable to cardiovascular bleeding or 
stroke
0 1 (0.1)
Noncardiovascular neurologic disorder 1 (0.1) 0
Noncardiovascular procedure or surgery 1 (0.1) 0
Renal disorder 1 (0.1) 0
Trauma 0 1 (0.1)
*  SUSTAIN-6 denotes Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with 
Type 2 Diabetes.
Table 1. Deaths from Noncardiovascular Causes in SUSTAIN-6.*
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